Falling Sales Force New Priorities At Roche

 
• By Elizabeth Cairns
  
Generate a summary of this article
Listen to this article
Beta

The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.    

Roche_Logo_Glass

COVID-19 was a nightmare on one level; on another, it was a bonanza for Roche Holding AG and its investors. With the pandemic in the rear-view mirror, sales of therapies for the virus have fallen markedly. This, and the appreciation of the Swiss franc against most currencies, left Roche’s first-quarter sales 6% lower than in the same period last year.

Key Takeaways

  • Roche’s Q1 sales fell 6% compared with the first three months of 2023, though they rose 2% on a constant currency basis

Knowing this was coming, the group has taken steps to improve its growth – and that means culling unpromising therapies...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D